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Background: 14-3-3σ is implicated in promoting tumor development of various malignancies. However, the clinical
relevance of 14-3-3σ in hepatocellular carcinoma (HCC) tumor progression and modulation and pathway elucidation
remain unclear.
Methods: We investigated 14-3-3σ expression in 109 HCC tissues by immunohistochemistry. Overexpression and
knockdown experiments were performed by transfection with cDNA or siRNA. Protein expression and cell migration
were determined by Western blot and Boyden chamber assay.
Results: In this study, we found that 14-3-3σ is abundantly expressed in HCC tumors. Stable or transient overexpression
of 14-3-3σ induces the expression of heat shock factor-1α (HSF-1α) and heat shock protein 70 (HSP70) in HCC cells.
Moreover, expression of 14-3-3σ significantly correlates with HSF-1α/HSP70 in HCC tumors and both 14-3-3σ and
HSP70 overexpression are associated with micro-vascular thrombi in HCC patients, suggesting that 14-3-3σ/HSP70
expression is potentially involved in cell migration/invasion. Results of an in vitro migration assay indicate that 14-3-3σ
promotes cell migration and that 14-3-3σ-induced cell migration is impaired by siRNA knockdown of HSP70. Finally,
14-3-3σ-induced HSF-1α/HSP70 expression is abolished by the knockdown of β-catenin or activation of GSK-3β.
Conclusions: Our findings indicate that 14-3-3σ participates in promoting HCC cell migration and tumor development
via β-catenin/HSF-1α/HSP70 pathway regulation. Thus, 14-3-3σ alone or combined with HSP70 are potential prognostic
biomarkers for HCC.
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The 14-3-3 family of proteins regulates multiple cellular
processes with a highly conserved homology among all
eukaryotic cells [1,2]. The 14-3-3σ isoform (also known as
stratifin, SFN) sequesters Cdc2-cyclin B and Cdc/Cdk
complexes in the cytoplasm, thereby inducing a G2 cell
cycle arrest [3,4]. Transcriptional expression of 14-3-3σ is
directly activated by the p53 tumor suppressor protein [5].
Epigenetic silencing of the 14-3-3σ (SFN) gene via CpG
methylation has been reported in various cancer cells, in-
cluding: breast, lung, liver, gastric cancer, ovarian and* Correspondence: liyingsung@ntu.edu.tw; jliou@nhri.org.tw
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reproduction in any medium, provided the orprostate cancers [6,7]. However, an increasing number of
studies have demonstrated that 14-3-3σ overexpression
promotes tumor progression [8-15]. An earlier study has
indicated that frequent hypermethylation of CpG islands
and the elimination of 14-3-3σ expression is found in hu-
man hepatocellular carcinoma (HCC) [16]. In contrast, in-
creased 14-3-3σ expression was found in a proteomic study
conducted to identify HCC associated protein markers [17].
These results, suggesting a “bipolar” role for 14-3-3σ, may
be due to specific tissues, cell types, signaling pathways or
may depend on the tumor-associated microenvironment.
Several molecular markers, including heat shock protein
70 (HSP70), glypican 3 (GPC3) and glutamine synthetase
(GS) were proposed as diagnostic markers of hepatocellular
nodules in cirrhosis and early HCC [18-24]. Among these
potential diagnostic factors, HSP70 is also considered as aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tial molecular chaperon and is activated in response to
stress and cell survival protection. It is tightly controlled
by the upstream transcriptional factor heat shock factor-1
(HSF-1). Recent studies have indicated that HSF-1 is a key
determinant in cancer progression and increased HSF-1
expression promotes HCC tumor invasion and metastasis
[27,28]. These results suggest that HSF-1 and HSP70 are
involved in facilitating HCC tumor development. Al-
though the molecular mechanism of HSF-1′s transcrip-
tional regulation is not well elucidated, some evidence
indicates that the activation of glycogen synthase kinase-
3β (GSK-3β) signaling attenuates HSF-1 activity [29-31].
GSK-3β is a serine/threonine protein kinase and a dysregu-
lation in GSK-3β signaling has been suggested to be critical
in influencing HCC cell growth [32]. GSK-3β phosphory-
lates β-catenin and subsequently facilitates β-catenin ubi-
quitination/degradation [33]. Accumulation or mutations
of β-catenin increase cell proliferation and are associated
with tumor progression in HCC [34-37].
The aim of the present study is to evaluate the role of
14-3-3σ in HCC and to investigate the potential molecular
targets of 14-3-3σ in modulating HCC development. Our
data indicates that 14-3-3σ expression is elevated in HCC
tumors and increased 14-3-3σ expression promotes HCC
tumor formation. Moreover, we show for the first time
that 14-3-3σ induces HSP70 expression which induces cell
migration via a β-catenin/HSF-1 dependent pathway. Our
results reveal that HSP70 is the downstream regulator of
14-3-3σ which modulates HCC development. A com-
bination of 14-3-3σ with HSF-1 and/or HSP70 might
therefore be considered as potential prognostic bio-
markers for HCC.Methods
Clinical specimens
Tissue samples were obtained from 109 HCC patients who
had undergone surgery for tumor resection at Taichung
Veterans General Hospital from January 1999 to December
2001. Twenty-nine patients (26.6%) developed tissue-proven
metastases, 3 to 87 months after resecting the primary
HCC. Slides from paraffin-embedded surgical specimens, in-
cluding the metastatic tumors and primary tumors with sur-
rounding non-cancerous liver parenchyma, were subjected
to immunohistochemical (IHC) staining. The IHC staining
results were compared with pathological features, clinical
parameters, including Barcelona-Clinic Liver Cancer
(BCLC) staging, and disease outcomes. This study was
approved by the Institutional Review Board of Taichung
Veterans General Hospital. The policy that no informed
consents are required for using these de-linked samples
for retrospective analysis was also approved by the Insti-
tutional Review Board.Immunohistochemical analysis
Procedure of IHC analysis was performed as previously de-
scribed [38-41]. 14-3-3σ, HSF-1 and HSP70 expressions in
paraffin-embedded tissues were detected by use of pri-
mary antibodies against 14-3-3σ (Bethyl Laboratories,
Montgomery, TX), HSF-1 and HSP70 (Santa Cruz Bio-
technology, Heidelberg, Germany). A negative control was
prepared by using the same staining procedure without pri-
mary antibodies. The IHC staining intensity was semiquan-
titatively scored by the Quick-score (Q-score) method based
on intensity and heterogeneity, as described previously
[38-43]. Briefly, the Q-score of a given tissue sample is the
sum of the intensity and heterogeneity scores and ranges
from 0 to 7. A Q-score ≥2 was considered as overexpressed
or positive expression and a Q-score <2 was considered nor-
mal or negative expression. Cases with <5% weakly stained
specimens were considered as negative expression.
Cell culture and stable cells
Huh-7 and SK-Hep1 cells were maintained in a humidified
incubator with 5% CO2 at 37°C in Dulbecco’s modified Ea-
gle’s medium (DMEM) (Gibco, Gaithersburg, MD) supple-
mented with 10% fetal bovine serum (FBS; Hyclone
Thermo Fisher Scientific, Waltham, MA), 100 U/mL peni-
cillin and 100 U/mL streptomycin. To establish stable cell
lines, 14-3-3σ cDNA was amplified by PCR and subcloned
into the p3XFlag-CMV vector. Huh-7 cells were transfected
with p3XFlag-CMV (control) and 14-3-3σ tagged with Flag
(14-3-3σ) by use of the Polyje™ transfection reagent accord-
ing to the manufacturer’s instructions (SignaGen Labora-
tories, Rockville, MD). The transfected cells were selected
using 500 μg/mL G418 (Biochrom AG, Berlin, Germany)
for 4 weeks. Single colonies of control and 14-3-3σ stable
clones (at least 4 in each cell line) were maintained in
DMEM with 10% FBS and 200 μg/mL G418.
Western blot analysis
Cells were lysed with ice cold RIPA buffer (0.5 mol/L
Tris–HCl, pH 7.4, 1.5 mol/L NaCl, 2.5% deoxycholic acid,
10% NP-40, 10 mmol/L EDTA; Millipore, Temecula, CA)
containing a protease inhibitor cocktail (Roche, Indian-
apolis, IN). Cell lysates were centrifuged at 16,100 g at 4°C
for 20 minutes. Protein concentrations were determined
and 20 μg of total proteins were applied to the gradient
SDS-PAGE gel and immunoblotted onto PVDF mem-
branes. The membranes were blocked, incubated with pri-
mary antibodies against Flag (Sigma-Aldrich, St. Louis,
MO), 14-3-3σ (Abcam PLC, Cambridge, UK), HSF-1, β-
catenin (Cell Signaling Technology, Beverly, MA) or
HSP70 (Santa Cruz Biotechnology, Heidelberg, Germany),
followed by an incubation with a secondary antibody con-
jugated horseradish-peroxidase in PBST. Protein levels
were determined by the use of enhanced chemilumines-
cence reagents.
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Cell proliferation was analyzed using a 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-dipheny ltetrazoliumbromide (MTT)
assay as previously reported [38]. Briefly, cells were seeded
in 96-well plates at a density of 1500 cells/well for 0, 24,
48 and 72 hours. 20 μL of MTT (5 mg/ml) (Sigma, St.
Louis, MO) was added to each well and incubated at 37°C
for 3 hours. Subsequently, the MTT solution was re-
moved, DMSO was added and the absorbance value (OD)
of each well was measured at 570 nm with a reference
wavelength of 690 nm.
Quantitative real-time PCR
Total RNA was extracted by use of the RNAspin Mini Kit
(QIAGEN, Alameda, CA) and cDNA was synthesized from
2 to 5 μg RNA by use of the random primers and Super-
Script™ III Reverse Transcriptase cDNA Synthesis Kit
(Invitrogen™ Life Technology, Carlsbad, CA). Quantita-
tive real-time PCR using SYBR Green (Kapabiosystem,
Woburn, MA) with specific oligonucleotide primers of
HSF-1 and HSP0 (Additional file 1: Table S1) were detected
by the AB 7900HT system (Applied Biosystems, Carlsbad,
CA). Applied Biosystems Relative Quantification Manager
Software version 1.2 was used to analyze the relative gene
expression in each sample by the comparative cycle thresh-
old (Ct) method. Gene expression was normalized to that
of glyceraldehyde-3-phosphate dehydrogenase.
Transfection and siRNA knockdown
Targeted knockdown of the 14-3-3σ gene expressions with
siRNA was purchased from Invitrogen™ including scram-
ble siRNA (Cat.No.12935-112). siRNA for targeting
HSP70 (sc-29352) and HSF-1 (sc-35611) were purchased
from Santa Cruz (Additional file 1: Table S2). Cell trans-
fections with siRNAs were performed using Lipofecta-
mine™ RNAiMAX (Invitrogen, Grand Island, NY) and
harvested at the indicated time for further analysis.
Migration assay
The cell migration assay was performed in a Boyden
chamber with Bio-coat cell migration chambers (Becton
Dickinson, Pont-de-Claix, France) as described previously
[38]. Cells were trypsinized, re-suspended with 0.1% bovine
serum albumin (BSA)–DMEM and added to the upper
wells (5 × 104 cells for Huh-7 stable cells, 2 × 104 cells for
SK-Hep1 cells). The cells then migrated to the bottom wells
that contained medium with 100 μg/mL fibronectin (Becton
Dickinson, Pont-de-Claix, France), epidermal growth factor
(20 ng/mL), and 10% BSA. The cells remaining on the upper
well were removed and the migrating cells in the bottom
well were stained and fixed with 0.1% crystal violet
containing 20% ethanol and 1% formaldehyde for 20 minutes.
Efficiency of cell migration was quantified by counting the
total number of migrating cells.Statistical analysis
One-way analysis of variance (ANOVA) was used to
analyze differences among clinicopathological variables by
14-3-3σ, HSP70 and HSF-1 expression. A Student’s t-test
was used to analyze differences between 2 experimental
groups. A P value <0.05 was considered statistically signifi-
cant and a P value of between 0.05 and 0.10 was consid-
ered marginally significant.
Results
Increased expression of 14-3-3σ in HCC tumors
To determine the expression of 14-3-3σ in HCC, paraffin-
embedded primary HCC tumors with surrounding non-
cancerous tissues of 109 patients were examined by immu-
nohistochemical staining. 14-3-3σ was undetected or was
stained with the background in non-cancerous cells but
had significantly increased expression in 84 of 109 (77.1%)
primary HCC tumors (Figure 1A, right panel and Table 1).
We next compared 14-3-3σ expression with the clinico-
pathological characteristics and found that increased 14-3-
3σ expression was significantly associated with surgical
margin (P = 0.008), capsular formation (P = 0.028) and
micro-vascular thrombi (P = 0.001). These results indicate
that expression of 14-3-3σ is associated with a more aggres-
sive tumor behavior and a poor prognosis (Table 1).
14-3-3σ upregulates HSF-1 and HSP70 expression in HCC
To investigate the role of 14-3-3σ on HCC tumor progres-
sion, we examined the expression level of 14-3-3σ in HCC
cell lines including Huh-7, HepG2, Hep3B, SK-Hep1 and
PLC-5. Although 14-3-3σ was detectable in all tested cell
lines, the expression of 14-3-3σ in Huh-7 was barely de-
tected but there was strong expression in SK-Hep1, PLC-5
and HepG2 cells (Figure 1B). In addition, we examined
14-3-3σ levels in non-HCC cells, including human umbil-
ical vein endothelial cells (HUVECs) and 293 cells, and
found the expression of 14-3-3σ was undetectable in these
cells (Additional file 1: Figure S1). We next established a
stable HCC cell line with 14-3-3σ overexpression in Huh-
7 cells. Huh-7 cells were transfected with p3XFlag-CMV
(control) and p3XFlag-14-3-3σ (14-3-3σ) vectors and se-
lected with G418 for 4 weeks. Single colonies were picked
and expression of 14-3-3σ was confirmed by Western blot
analysis of Flag and 14-3-3σ (Additional file 1: Figure S2A
and B). Clone 2 of 14-3-3σ and clone 1 of the control were
used for the following experiments. To examine whether
14-3-3σ regulates HCC growth, the cell proliferation rate
was determined by an MTT assay. 14-3-3σ overexpression
has no significant effect on cell proliferation in compari-
son to the control cells (Figure 1C).
To explore the downstream factors of 14-3-3σ which
are involved in modulating HCC tumor progression, we
performed a gene expression profile analysis of 14-3-3σ
overexpresion (Additional file 1: Table S3 and Table S4).
Figure 1 14-3-3σ overexpression induces tumor growth. (A) A represtative expression of 14-3-3σ in a primary HCC tumor and in a negative
control examined by immunohistochemical analysis. T: tumor; N: non-cancerous cells. Original magnification: ×200. (B) 14-3-3σ expression levels
in HCC cell lines were determined by Western blot analysis. Actin was used as a loading control. (C) The rate of cell proliferation was determined
by an MTT assay. Scale bars: mean ± SD.
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identified HSP70 as one of the potential targets. Earlier
studies have suggested that HSP70 serves as a potential
biomarker for early detection of HCC [18-23]. To validate
whether HSP70 expression is induced by 14-3-3σ, we de-
termined HSP70 and its transcriptional activator, HSF-1α
levels by Western blot analysis. Stable cells with increased
14-3-3σ expression significantly induced HSF-1α as well
as HSP70 expression levels (Figure 2A). Induction of HSF-
1α/HSP70 was further validated on the RNA level by
quantitative real-time PCR analysis (Figure 2B). We next
performed transient transfection experiments of 14-3-3σ
overexpression in HCC cells. Transient overexpression of
14-3-3σ significantly induced HSF-1α/HSP70 expression in
Huh-7 cells (Figure 2C). Furthermore, 14-3-3σ-induced
HSF-1α and HSP70 expressions were attenuated by siRNA
knockdown of 14-3-3σ (Figure 2D) and HSF-1α (Additional
file 1: Figure S3). In addition, transfection of 14-3-3σ siRNA
suppressed HSF-1α and HSP70 expressions in SK-Hep1
cells (Figure 2E). These results indicate that HSF-1α/HSP70
expressions are induced by 14-3-3σ in HCC.
Association of 14-3-3σ expression with HSF-1α and HSP70
in HCC tissues
To further show that 14-3-3σ induces HSF-1α/HSP70 in
HCC, we examined and compared the expression of HSF-
1α/HSP70 with 14-3-3σ by immunohistochemical staining
in clinical HCC specimens. Both HSF-1α and HSP70expression were correlatively increased in HCC tumors
(Figure 3A). The expression of HSF-1α and HSP70 stained
positively in 93 of 109 (85.3%) and 66 of 109 (60.6%) of
primary HCC tumors, respectively. Furthermore, expres-
sion of 14-3-3σ positive tumors was significantly correlated
with HSF-1α (P < 0.001) and HSP70 (P = 0.032) (Figure 3B).
We next analyzed the correlation of HSP70 expression with
clinicopathological characteristics and found that positive
HSP70 expression was significantly associated with micro-
vascular thrombi (P = 0.019) and alpha–fetoprotein levels
(P = 0.009) (Table 1).
14-3-3σ/HSP70 enhanced HCC cell migration
While comparing the expression of 14-3-3σ and HSP70
with clinicopathological parameters, the most significant
factor is the appearance of micro-vascular thrombi which
positivity correlates with both 14-3-3σ and HSP70 (Table 1).
Increased micro-vascular thrombi imply enhanced tumor
migration/invasion. We therefore wanted to determine
whether HSP70 expression influences 14-3-3σ-induced
cell migration/invasion. We first investigated whether
14-3-3σ overexpression affects cell migration/invasion.
14-3-3σ overexpression significantly facilitates cell migra-
tion (Figure 4A), although an unexpected effect of sup-
pressing invasion was found (Additional file 1: Figure S4).
Moreover, the 14-3-3σ induced migratory ability was sig-
nificantly abrogated by siRNA knockdown in both of the
14-3-3σ stable cells (Figure 4B) and SK-Hep1 cells
Table 1 Correlation of 14-3-3σ and HSP70 with clinicopathological characteristics in primary HCC patients
Parameters 14-3-3σ expression (Q-score ≥ 2) % (n) p-value Hsp70 expression (Q-score ≥ 2) % (n) p-value
Overall (n = 109) 77.1% (84) 60.6% (66)
Age 0.080† NS
< 60 years (n = 56) 83.9% (47) 66.1% (37)
≥ 60 years (n = 53) 69.8% (37) 54.7% (29)
Gender NS 0.097†
Male (n = 82) 79.3% (65) 56.1% (46)
Female (n = 27) 70.4% (19) 74.1% (20)
Histology grade NS 0.060†
1 (n = 7) 71.4% (5) 28.6% (2)
2 (n = 77) 74.0% (57) 58.4% (45)
3 (n = 25) 88.0% (22) 76.0% (19)
Types of surgery NS NS
Wedge resection (n = 39) 69.2% (27) 56.4% (22)
Segmentectomy (n = 54) 79.6% (43) 64.8% (35)
Lobectomy (n = 16) 87.5% (14) 56.3% (9)
Surgical margin 0.008* NS
Free (n = 83) 71.1% (59) 61.4% (51)
Involved (n = 26) 96.2% (25) 57.7% (15)
BCLC staging NS 0.079†
Not available (n = 5)
Early (stage A1 to A4) (n = 56) 69.6% (39) 51.8% (29)
Intermediate (stage B) (n = 46) 82.6% (38) 67.4% (31)
Advanced (stage C) (n = 2) 100.0% (2) 100.0% (2)
Tumor size 0.062† 0.062†
≥ 5.0 cm (n = 34) 88.2% (30) 73.5% (25)
< 5.0 cm (n = 75) 72.0% (54) 54.7% (41)
Tumor multiplicity NS NS
Single (n = 84) 78.6% (66) 63.1% (53)
Multiple (n = 25) 72.0% (18) 52.0% (13)
Capsular formation 0.028* NS
Not available (n = 8)
Yes (n = 59) 69.5% (41) 57.6% (34)
No (n = 42) 88.1% (37) 66.7% (28)
Micro-vascular thrombi 0.001* 0.019*
Yes (n = 48) 91.7% (44) 72.9% (35)
No (n = 61) 65.6% (40) 50.8% (31)
Liver cirrhosis NS NS
Not available (n = 3)
Yes (n = 55) 76.4% (42) 58.2% (32)
No (n = 51) 78.4% (40) 64.7% (33)
Viral hepatitis NS NS
Not available (n = 7)
Hepatitis B (n = 54) 79.6% (43) 61.1% (33)
Hepatitis C (n = 30) 70.0% (21) 56.7% (17)
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Table 1 Correlation of 14-3-3σ and HSP70 with clinicopathological characteristics in primary HCC patients (Continued)
Both (n = 15) 80.0% (12) 60.0% (9)
None (n = 3) 66.7% (2) 66.7% (2)
Alpha-fetoprotein level NS 0.009*
Not available (n = 12)
≧ 80 ng/ml (n = 35) 80.0% (28) 77.1% (27)
< 80 ng/ml (n = 62) 74.2% (46) 50.0% (31)
Subsequent extrahepatic metastasis NS NS
Yes (n = 29) 82.8%(24) 65.5% (19)
No (n = 80) 75.0%(60) 58.8% (47)
BCLC, Barcelona-Clinic Liver Cancer; NS, not significant; Q-score, Quick-score.
*p < 0.05; †0.05 < p < 0.10.
Figure 2 14-3-3σ induces HSF-1 and HSP70 expression. (A) Increased expression of HSF-1 and HSP70 induced by 14-3-3σ stable overexpression
was determined by Western blotting and (B) real-time PCR analysis. Lanes 1–4 indicate as 4 different stable clones selected from the single colonies.
Scale bars: mean ± SD. (C) Transient transfection of 14-3-3σ overexpression induced HSF-1 and HSP70 expression. (D) Knockdown of 14-3-3σ with
siRNA suppressed HSF-1 and HSP70 expression in 14-3-3σ stable cells and (E) SK-Hep1 cells. Expression of HSF-1, HSP70, 14-3-3σ and Flag was
determined by Western blot analysis. Actin was used as a loading control.
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Figure 3 Correlation of 14-3-3σ expression with HSF-1 and HSP70 in HCC tumors. (A) Representative expression of HSF-1 and HSP70 in
primary HCC tumors as well as negative control was examined by immunohistochemical analysis. Original magnification, ×200. (B) 14-3-3σ
significantly correlates with HSF-1 and HSP70 expression in primary HCC tumors as analyzed by the Chi-square test.
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expression results in promoting HCC cell migration. To
further investigate whether HSP70 is involved in 14-3-3σ-
induced cell migration, SK-Hep1 cells overexpressing 14-
3-3σ were transfected with HSP70 siRNAs. Knockdown of
HSP70 significantly impaired 14-3-3σ-induced cell migra-
tion in stable (Figure 4D) and in SK-Hep1 cells (Figure 4E).
These results indicate that HSP70 is an important down-
stream regulator of 14-3-3σ which in turn regulates HCC
cell migration and tumor progression.
14-3-3σ induces HSF-1α expression via a GSK-3β/β-catenin
dependent mechanism
HSP70 is transcriptionally upregulated by HSF-1α activa-
tion. The molecular pathway controlling HSF-1α expres-
sion has never been well characterized. Earlier studies
indicate that GSK-3β modulates HSF-1α activity [29-31]
and the stability of β-catenin is known to be the major
downstream event regulated by GSK-3β. We thus postu-
lated that GSK-3β/β-catenin may be involved in regulating
14-3-3σ-induced HSF-1α/HSP70 expression. To prove this
hypothesis, 14-3-3σ overexpressing and control cells were
transfected with β-catenin or scramble siRNA and the
expression of HSF-1α was determined by Western blot ana-
lysis. Knockdown of β-catenin significantly abrogates 14-3-
3σ-induced HSF-1α expression (Figure 5A). The effects of
HSF-1α and HSP70 suppressive expressions by β-catenin knockdown were also confirmed in SK-Hep1 cells
(Figure 5B). In addition, we found that 14-3-3σ overex-
pression increases β-catenin expression levels (Figure 5A
and C). Transient activation of GSK-3β by transfection of
wild type (GSK-3β WT) or constitutively activated mutant
(GSK-3β CA) significantly attenuates 14-3-3σ–induced β-
catenin and HSF-1α expression (Figure 5C). We next ex-
amined whether β-catenin is involved in regulating cell
migration of HCC. The 14-3-3σ/control cells and SK-
Hep1 cells were transfected with siRNA of β-catenin and
the migration ability was determined by a trans-well assay.
Knockdown of β-catenin significantly reduced cell migra-
tion of 14-3-3σ/control cells (Figure 5D) and SK-Hep1
cells (Figure 5E). These results suggest that 14-3-3σ in-
duced HSF-1α/HSP70 expression and cell migration is
mediated by the GSK-3β/β-catenin signaling pathway.
Discussion
Our results show that 14-3-3σ plays major roles in HCC.
We initially showed that 14-3-3σ is overexpressed in HCC
tumors and that HSP70, one of the downstream factors of
14-3-3σ, is upregulated by 14-3-3σ and this action is medi-
ated by the GSK-3β/β-catenin/HSF-1α signaling pathway.
Additionally, 14-3-3σ modulates HSP70 to promote cell
migration in HCC. These findings suggest that 14-3-3σ to-
gether with β-catenin/HSF-1α and HSP70 enhance HCC
tumor progression. 14-3-3σ was shown to both enhance
Figure 4 14-3-3σ induces cell migration via an increase of HSP70 expression. (A) Migratory ability of control and 14-3-3σ overexpressed
Huh-7 cells was determined by a Boyden chamber assay. (B) Knockdown of 14-3-3σ with siRNA suppressed cell migration in 14-3-3σ stably
overexpressed Huh-7 cells and (C) SK-Hep1 cells. (D) Knockdown of HSP70 with siRNA attenuated 14-3-3σ-induced cell migration in stable cells
and (E) SK-Hep1 cells. Scale bars: mean ± SD. *P < 0.05, **P < 0.01.
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tumor types pointing to a cell type specific effect of 14-3-
3σ. For instance, 14-3-3σ is frequently DNA hypermethy-
lation and subsequently silenced in lung cancers. However,
variations of 14-3-3σ expression levels were found in het-
erogeneous lung cancers [44]. Recent studies have demon-
strated that a highly methylated SFN promoter is found in
normal lung tissue and in adenocarcinomas [13], however,
14-3-3σ is overexpressed in early invasive adenocarcinoma
[13,15]. These studies indicate that 14-3-3σ expression in
tumors is modulated by a complicated regulatory mechan-
ism. In addition, analysis of 14-3-3σ and HSP70 expres-
sions with clinicopathological parameters reveal that both
14-3-3σ and HSP70 are correlated with micro-vascular
thrombi in HCC patients. We have shown that 14-3-3σ
overexpression induces HCC cell migration (Figure 4A)
but unexpectedly reduces cell invasion (Additional file 1:
Figure S4). These results reveal that the 14-3-3σ promo-
tion of HCC cell invasion and tumor metastasis arecomplicated processes and other essential synergistic regu-
lators are probably involved. By simply elevating 14-3-3σ
expression without activating other synergistic factors may
result in a reciprocal phenomenon. This may also explain
the duplicitous role of 14-3-3σ reported in earlier studies
[16,17]. In addition, since extracellularly secreted 14-3-3σ
has been shown to affect muscle remodeling in keratinocyte
associated fibroblasts [44], we postulate that the surround-
ing stromal cells associated with tumors play important
roles in 14-3-3σ-promoting HCC tumor progression. 14-3-
3σ might synergize with other signals from its micro-
environment milieu and tumor-stromal interactions may
therefore be critical for tumor progression. Further investi-
gation needs to be done to ascertain if 14-3-3σ combines
with additional factors and if 14-3-3σ’s expression in tumor
heterogeneity is found in distinct stages of HCC.
We found that either the moderate (clone 1 and 2) or
extremely higher (clone 3 and 4) expression of 14-3-3σ
(Additional file 1: Figure S2B) upregulate the expression of
Figure 5 14-3-3σ induces HSF-1 expression via regulating β-catenin. (A) 14-3-3σ-induced HSF-1 expression was abolished by knockdown of
β-catenin in stable cells and (B) SK-Hep1 cells. (C) 14-3-3σ-induced HSF-1 expression was attenuated by overexpression with wild type (WT) and
constitutively activated (CA) mutant of GSK-3β. Expression of β-catenin, HSF-1, HSP70 and Flag was determined by Western blot analysis. Actin
was used as a loading control. (D) Migratory ability was determined by a Boyden chamber assay. Knockdown of β-catenin with siRNA suppressed
cell migration in 14-3-3σ stably overexpressed cells and (E) SK-Hep1 cells. Scale bars: mean ± SD. *P < 0.05, **P < 0.01.
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gest that the appropriately increased 14-3-3σ expression
may be sufficient to regulate HCC tumor progression and
an excess of 14-3-3σ have no further effect on HSF-1α
and HSP70 expression (Figure 2A and B).
In this work, we show for the first time that HSF-1α/
HSP70 is regulated by β-catenin in HCC. β-catenin is an
important transcriptional regulator in promoting cell pro-
liferation. Our recently published data indicates that 14-3-3σ promotes mouse embryonic stem cell proliferation via
enhancing β-catenin stability [45], suggesting that 14-3-3σ
may modulate the β-catenin signal pathway to promote
cell proliferation. In addition, earlier studies have indicated
that β-catenin signaling regulates GS expression and is in-
volved in glutamine metabolism [46,47]. Since β-catenin is
known to be a pivotal factor in promoting HCC develop-
ment [34-37], both HSF-1α/HSP70 and GS are potential
downstream targets of β-catenin. Whether the potential
Liu et al. BMC Cancer 2014, 14:425 Page 10 of 11
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HSF-1 and GS are regulated by β-catenin needs further
investigation.
Conclusion
Our results link 14-3-3σ with β-catenin/HSF-1α/HSP70
and these regulators work as a network in promoting
HCC development. We also provide evidence at the cellu-
lar and clinical tissue levels to suggest that 14-3-3σ is the
upstream modulator of β-catenin and HSF-1α/HSP70 in
HCC. 14-3-3σ combined with other potential markers in-
cluding HSP70 might be used as potential prognostic bio-
markers for HCC.
Additional file
Additional file 1 Table S1. Oligonucleotide sequences for Q-PCR. Table
S2. Oligonucleotide sequences of small interfering RNAs. Table S3. Gene
expression (>4 fold) induced by 14-3-3σ overexpression in Huh-7 stable
cells was analyzed by microarray analysis. The total RNA samples were
extracted from control and 14-3-3σ overexpressed cells using Qiagen
RNeasy Mini Kit (Qiagen, Valencia, CA) and the microarray analysis was
processed according to the manufacturers’ instructions of Affymetrix Inc.
(Santa Clara, CA). Table S4. Gene expression (<4 fold) suppressed by
14-3-3σ overexpression was analyzed by microarray analysis. Figure S1.
Expression of 14-3-3σ in non-HCC (HUVECs and 293) and HCC (Huh-7,
HepG2 and SK-Hep1) cells was determined by Western blotting analysis.
Actin was used as loading control. Figure S2. Establishment of 14-3-3σ
stable cell lines. Huh-7 cells were transfected with p3XFlag-CMV (control)
and Flag-tagged 14-3-3σ overexpression vectors, followed by selection
with G418 for 4 Weeks. Expression of 14-3-3σ in stable cells was
confirmed by Western blot analysis of (A) Flag and (B) 14-3-3σ (4 clones for
each of control and 14-3-3σ). Actin was used as loading control. Figure S3.
14-3-3σ-induced HSP70 expression was attenuated by knockdown of HSF-1
with siRNA. Control and 14-3-3σ stable cells were transfected with scramble or
HSF-1 siRNA. Expression of HSF-1 and HSP70 was determined by Western
blotting analysis. Actin was used as loading control. Figure S4. 14-3-3σ reduces
cell invasion. Efficacy of cell invasion was examined by two-chamber analysis.
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